Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $10
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $17 to $10.
Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $17 to $10.